11/3/2026

speaker
Angela
Conference Call Operator

Good morning and thank you for standing by. Welcome to Madrigal Pharmaceuticals' third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. As a reminder, today's conference call is being recorded. I would now like to introduce Ms. Tina Ventura, Chief Investor Relations Officer. Please go ahead.

speaker
Tina Ventura
Chief Investor Relations Officer

Thanks. Good morning, everyone, and thank you for joining us to discuss Madrigal's third quarter 2026 results. We issued a press release this morning and posted the slide deck to accompany this webcast on the investor relations section of our website. On the call with me today are Bill Sibold, Chief Executive Officer, Dave Soergel, Chief Medical Officer, and Mardi Dier, Chief Financial Officer. They will provide prepared remarks followed by Q&A. Please note that on slide two, we will be making certain forward-looking statements today. We refer you to our FDC filings for discussion of the risks that may cause actual results to differ from the forward-looking statements. With that, I will now turn the call over to Bill on slide three.

speaker
Bill Sibold
Chief Executive Officer

Thanks, Tina, and thank you all for joining. The business is performing exceptionally well. ResDifera is growing rapidly and the MASH market is accelerating. ResDifera's best in disease profile and our team's strong execution have established ResDifera as the foundational therapy in MASH. I'll summarize a few highlights. First, we delivered a $431 million quarter, crossed the $1 billion milestone in year-to-date net sales, and are now annualizing at more than $1.7 billion based on this quarter's results. We're continuing to steadily add patients and believe we're well on our way to mega blockbuster status. Second, the U.S. F2-F3 mash market is accelerating, on track to grow more than 30% this year. When you combine rapid market growth with redifference patent protection expected into 2045, it's hard to find a more attractive growth opportunity in biotech, and third, we're advancing our F4C program with the same objective that has guided us in F2F3, to be first and best. Our ongoing MaestroNAS outcomes trial positions us to deliver the first approved therapy for F4C. Our new Maestro CSPH Phase III trial is designed to be a practice-shaping trial that we expect to extend our competitive advantage and strengthen our long-term leadership. Let's move to our Q3 results, where I'll cover ResDifera and the expanding MASH market. Dave will discuss our pipeline progress, and Mardi will close with our financials. Turning to slide five, third quarter 2026 net sales were $431 million, up 50% year over year. This performance reflects growing demand for ResDifera and outstanding execution by our team. We built a broad and durable prescriber base early, and now we are driving depth. The positive experience our target specialists are having with ResDipper in the real world is translating into action. They are prescribing it more often. That growing depth combined with excellent access, ResDipper's differentiated profile, and strong patient adherence is why we continue to steadily add patients. As shown on slide six, we ended the third quarter with more than 55,850 active risk different patients, compared to more than 29,500 a year ago. That's nearly twice as many patients on therapy. As a reminder, this is the number of patients actively on therapy at quarter end, net of discontinuations. Slide seven shows why we are so confident in the opportunity ahead. Our latest research shows that the market is accelerating. As we said, at the end of 2025, the diagnosed US F2-F3 mass population had grown nearly 50% in two years to 460,000 patients. As of June 30th of this year, we estimate the market expanded to more than 530,000 patients and is on track to grow more than 30% by the end of 2026. The growth in this market is primarily being driven by an increase in awareness and diagnosis. Slide 8 makes clear just how much runway remains. The MASH diagnosis rate is still only around 10%, and ResDipra has penetrated approximately 10% of the market. At 10% of 10%, we are only about 1% into the total opportunity. With more than $1 billion in year-to-date net sales, we are at the very beginning of what we believe will become one of the largest specialty markets in the industry. As noted on Slide 10, Building a successful medicine takes much more than a positive top-line readout. That's only the beginning of the story. Launch success depends on several important drivers. Labels matter. Boxed warnings and burdensome monitoring requirements create barriers. You need efficacy, safety, and tolerability to translate into a positive real-world experience. And you need a medicine that is easy to prescribe, easy to take, and easy to stay on. Then there's execution, the right infrastructure, the field team, medical affairs, reimbursement, market access, fulfillment, and patient support all working together to get patients on therapy and keep them on therapy. Building that system takes experience, resources, and time. Ten quarters into launch, those questions have been answered for ResDifera as shown on slide 11. We have what we believe is the best in disease profile. Red Zipper is highly effective across each patient's subtype. It's well tolerated and simple to use, and with nearly 56,000 patients on therapy, its safety profile is exceptionally well-defined, which actually may be the most important thing. That's the real-world profile you want for a chronic disease. We also built the industry-leading infrastructure, and we are continuously improving it. We've done the hard work to wire the system and have set an extremely high bar. This doesn't just happen overnight, and it is difficult to replicate. We already have thousands of prescribers and more than two years of real-world experience. Any new entrant will have to build what we are already optimizing and answer the question, what problem are they trying to solve? We have delivered one of the best specialty launches of the last decade and established clear leadership in F2F3 by being first and best. We will leverage this formidable advantage in F4C as well. Let's turn to slide 12. The F4C market is increasingly attractive. It's a rapidly growing multibillion-dollar market opportunity. We now estimate 360,000 addressable F4C patients in the U.S., up more than 45% from the 245,000 we previously shared. That is larger than the F2F3 patient population when we launched ResDifera. Expanding into F4C could double Red Dipper's opportunity and bring patients their first approved therapy. We've also seen recently that competitors have modified their programs, increased their study sizes, and delayed their timelines with the earliest potential entrant now not expected until 2030. Our lead in F4C has widened. Micronash Outcomes puts us in a unique position to be first to market. Events continue to accrue in this study, and we're now anticipating a readout in late 2027. We are confident in resiferate potential in F4C and are exceptionally well-positioned to lead. The addition of our new Phase III trial, Maestro CSPH, raises the bar for the field. It builds on Maestro NASH outcomes while unlocking new opportunities to shape clinical practice as the treatment landscape continues to evolve. This trial will benefit from what we've learned about F4C over the last five years and is another tangible demonstration of our leadership in MASH. Our objective remains clear. Be first and best in F4C. Dave will walk you through our plans. Over to you, Dave.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation